id	sid	tid	token	lemma	pos
dpc-5967	1	1	dermatology	dermatology	NOUN
dpc-5967	1	2	:	:	PUNCT
dpc-5967	1	3	practical	practical	ADJ
dpc-5967	1	4	and	and	CCONJ
dpc-5967	1	5	conceptual	conceptual	ADJ
dpc-5967	1	6	letter	letter	NOUN
dpc-5967	1	7	to	to	ADP
dpc-5967	1	8	the	the	DET
dpc-5967	1	9	editor	editor	NOUN
dpc-5967	1	10	|	|	ADV
dpc-5967	1	11	dermatol	dermatol	ADJ
dpc-5967	1	12	pract	pract	NOUN
dpc-5967	1	13	concept	concept	NOUN
dpc-5967	1	14	.	.	PUNCT
dpc-5967	2	1	2025;15(4):5967	2025;15(4):5967	NUM
dpc-5967	2	2	1	1	NUM
dpc-5967	2	3	the	the	DET
dpc-5967	2	4	efficacy	efficacy	NOUN
dpc-5967	2	5	and	and	CCONJ
dpc-5967	2	6	safety	safety	NOUN
dpc-5967	2	7	of	of	ADP
dpc-5967	2	8	nemolizumab	nemolizumab	NOUN
dpc-5967	2	9	in	in	ADP
dpc-5967	2	10	patients	patient	NOUN
dpc-5967	2	11	with	with	ADP
dpc-5967	2	12	prurigo	prurigo	PROPN
dpc-5967	2	13	nodularis	nodularis	PROPN
dpc-5967	2	14	:	:	PUNCT
dpc-5967	2	15	a	a	DET
dpc-5967	2	16	systematic	systematic	ADJ
dpc-5967	2	17	review	review	NOUN
dpc-5967	2	18	and	and	CCONJ
dpc-5967	2	19	meta	meta	NOUN
dpc-5967	2	20	-	-	PUNCT
dpc-5967	2	21	analysis	analysis	NOUN
dpc-5967	2	22	of	of	ADP
dpc-5967	2	23	randomized	randomized	ADJ
dpc-5967	2	24	controlled	control	VERB
dpc-5967	2	25	trials	trial	NOUN
dpc-5967	2	26	hicham	hicham	PROPN
dpc-5967	2	27	titou1	titou1	PROPN
dpc-5967	2	28	1	1	NUM
dpc-5967	2	29	department	department	NOUN
dpc-5967	2	30	of	of	ADP
dpc-5967	2	31	dermatology	dermatology	NOUN
dpc-5967	2	32	-	-	PUNCT
dpc-5967	2	33	venereology	venereology	NOUN
dpc-5967	2	34	,	,	PUNCT
dpc-5967	2	35	avicenne	avicenne	PROPN
dpc-5967	2	36	military	military	ADJ
dpc-5967	2	37	hospital	hospital	NOUN
dpc-5967	2	38	,	,	PUNCT
dpc-5967	2	39	faculty	faculty	NOUN
dpc-5967	2	40	of	of	ADP
dpc-5967	2	41	medicine	medicine	NOUN
dpc-5967	2	42	and	and	CCONJ
dpc-5967	2	43	pharmacy	pharmacy	NOUN
dpc-5967	2	44	,	,	PUNCT
dpc-5967	2	45	cadi	cadi	NOUN
dpc-5967	2	46	ayyad	ayyad	PROPN
dpc-5967	2	47	university	university	PROPN
dpc-5967	2	48	,	,	PUNCT
dpc-5967	2	49	marrakech	marrakech	NOUN
dpc-5967	2	50	,	,	PUNCT
dpc-5967	2	51	morocco	morocco	PROPN
dpc-5967	2	52	citation	citation	NOUN
dpc-5967	2	53	:	:	PUNCT
dpc-5967	2	54	titou	titou	PROPN
dpc-5967	2	55	h.	h.	PROPN
dpc-5967	3	1	the	the	DET
dpc-5967	3	2	efficacy	efficacy	NOUN
dpc-5967	3	3	and	and	CCONJ
dpc-5967	3	4	safety	safety	NOUN
dpc-5967	3	5	of	of	ADP
dpc-5967	3	6	nemolizumab	nemolizumab	NOUN
dpc-5967	3	7	in	in	ADP
dpc-5967	3	8	patients	patient	NOUN
dpc-5967	3	9	with	with	ADP
dpc-5967	3	10	prurigo	prurigo	PROPN
dpc-5967	3	11	nodularis	nodularis	PROPN
dpc-5967	3	12	:	:	PUNCT
dpc-5967	3	13	a	a	DET
dpc-5967	3	14	systematic	systematic	ADJ
dpc-5967	3	15	review	review	NOUN
dpc-5967	3	16	and	and	CCONJ
dpc-5967	3	17	meta	meta	NOUN
dpc-5967	3	18	-	-	PUNCT
dpc-5967	3	19	analysis	analysis	NOUN
dpc-5967	3	20	of	of	ADP
dpc-5967	3	21	randomized	randomized	ADJ
dpc-5967	3	22	controlled	control	VERB
dpc-5967	3	23	trials	trial	NOUN
dpc-5967	3	24	.	.	PUNCT
dpc-5967	4	1	dermatol	dermatol	NOUN
dpc-5967	4	2	pract	pract	PROPN
dpc-5967	4	3	concept	concept	NOUN
dpc-5967	4	4	.	.	PUNCT
dpc-5967	5	1	2025;15(4):5967	2025;15(4):5967	NUM
dpc-5967	5	2	.	.	PUNCT
dpc-5967	6	1	doi	doi	PROPN
dpc-5967	6	2	:	:	PUNCT
dpc-5967	6	3	https://doi.org/10.5826/dpc.1504a5967	https://doi.org/10.5826/dpc.1504a5967	PROPN
dpc-5967	6	4	accepted	accept	VERB
dpc-5967	6	5	:	:	PUNCT
dpc-5967	6	6	april	april	PROPN
dpc-5967	6	7	9	9	NUM
dpc-5967	6	8	,	,	PUNCT
dpc-5967	6	9	2025	2025	NUM
dpc-5967	6	10	;	;	PUNCT
dpc-5967	6	11	published	publish	VERB
dpc-5967	6	12	:	:	PUNCT
dpc-5967	7	1	october	october	PROPN
dpc-5967	7	2	2025	2025	NUM
dpc-5967	7	3	copyright	copyright	NOUN
dpc-5967	7	4	:	:	PUNCT
dpc-5967	7	5	©	©	PROPN
dpc-5967	7	6	2025	2025	NUM
dpc-5967	7	7	titou	titou	NOUN
dpc-5967	7	8	.	.	PUNCT
dpc-5967	8	1	this	this	PRON
dpc-5967	8	2	is	be	AUX
dpc-5967	8	3	an	an	DET
dpc-5967	8	4	open	open	ADJ
dpc-5967	8	5	-	-	PUNCT
dpc-5967	8	6	access	access	NOUN
dpc-5967	8	7	article	article	NOUN
dpc-5967	8	8	distributed	distribute	VERB
dpc-5967	8	9	under	under	ADP
dpc-5967	8	10	the	the	DET
dpc-5967	8	11	terms	term	NOUN
dpc-5967	8	12	of	of	ADP
dpc-5967	8	13	the	the	DET
dpc-5967	8	14	creative	creative	ADJ
dpc-5967	8	15	commons	common	NOUN
dpc-5967	8	16	attribution	attribution	NOUN
dpc-5967	8	17	-	-	PUNCT
dpc-5967	8	18	noncommercial	noncommercial	ADJ
dpc-5967	8	19	license	license	NOUN
dpc-5967	8	20	(	(	PUNCT
dpc-5967	8	21	by	by	ADP
dpc-5967	8	22	-	-	PUNCT
dpc-5967	8	23	nc-4.0	nc-4.0	NOUN
dpc-5967	8	24	)	)	PUNCT
dpc-5967	8	25	,	,	PUNCT
dpc-5967	8	26	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-5967	8	27	,	,	PUNCT
dpc-5967	8	28	which	which	PRON
dpc-5967	8	29	permits	permit	VERB
dpc-5967	8	30	unrestricted	unrestricted	ADJ
dpc-5967	8	31	noncommercial	noncommercial	ADJ
dpc-5967	8	32	use	use	NOUN
dpc-5967	8	33	,	,	PUNCT
dpc-5967	8	34	distribution	distribution	NOUN
dpc-5967	8	35	,	,	PUNCT
dpc-5967	8	36	and	and	CCONJ
dpc-5967	8	37	reproduction	reproduction	NOUN
dpc-5967	8	38	in	in	ADP
dpc-5967	8	39	any	any	DET
dpc-5967	8	40	medium	medium	NOUN
dpc-5967	8	41	,	,	PUNCT
dpc-5967	8	42	provided	provide	VERB
dpc-5967	8	43	the	the	DET
dpc-5967	8	44	original	original	ADJ
dpc-5967	8	45	authors	author	NOUN
dpc-5967	8	46	and	and	CCONJ
dpc-5967	8	47	source	source	NOUN
dpc-5967	8	48	are	be	AUX
dpc-5967	8	49	credited	credit	VERB
dpc-5967	8	50	.	.	PUNCT
dpc-5967	9	1	funding	funding	NOUN
dpc-5967	9	2	:	:	PUNCT
dpc-5967	9	3	none	none	NOUN
dpc-5967	9	4	.	.	PUNCT
dpc-5967	10	1	competing	compete	VERB
dpc-5967	10	2	interests	interest	NOUN
dpc-5967	10	3	:	:	PUNCT
dpc-5967	10	4	none	none	NOUN
dpc-5967	10	5	.	.	PUNCT
dpc-5967	11	1	authorship	authorship	NOUN
dpc-5967	11	2	:	:	PUNCT
dpc-5967	11	3	all	all	DET
dpc-5967	11	4	authors	author	NOUN
dpc-5967	11	5	have	have	AUX
dpc-5967	11	6	contributed	contribute	VERB
dpc-5967	11	7	significantly	significantly	ADV
dpc-5967	11	8	to	to	ADP
dpc-5967	11	9	this	this	DET
dpc-5967	11	10	publication	publication	NOUN
dpc-5967	11	11	.	.	PUNCT
dpc-5967	12	1	corresponding	correspond	VERB
dpc-5967	12	2	author	author	NOUN
dpc-5967	12	3	:	:	PUNCT
dpc-5967	12	4	hicham	hicham	PROPN
dpc-5967	12	5	titou	titou	PROPN
dpc-5967	12	6	,	,	PUNCT
dpc-5967	12	7	dermatologist	dermatologist	NOUN
dpc-5967	12	8	,	,	PUNCT
dpc-5967	12	9	department	department	NOUN
dpc-5967	12	10	of	of	ADP
dpc-5967	12	11	dermatology	dermatology	NOUN
dpc-5967	12	12	-	-	PUNCT
dpc-5967	12	13	venereology	venereology	NOUN
dpc-5967	12	14	,	,	PUNCT
dpc-5967	12	15	avicenne	avicenne	PROPN
dpc-5967	12	16	military	military	ADJ
dpc-5967	12	17	hospital	hospital	NOUN
dpc-5967	12	18	,	,	PUNCT
dpc-5967	12	19	cadi	cadi	NOUN
dpc-5967	12	20	ayyad	ayyad	PROPN
dpc-5967	12	21	university	university	PROPN
dpc-5967	12	22	,	,	PUNCT
dpc-5967	12	23	marrakech	marrakech	NOUN
dpc-5967	12	24	,	,	PUNCT
dpc-5967	12	25	morocco	morocco	PROPN
dpc-5967	12	26	.	.	PUNCT
dpc-5967	13	1	orcid	orcid	NOUN
dpc-5967	13	2	:	:	PUNCT
dpc-5967	13	3	0000	0000	NUM
dpc-5967	13	4	-	-	PUNCT
dpc-5967	13	5	0001	0001	NUM
dpc-5967	13	6	-	-	PUNCT
dpc-5967	13	7	9290	9290	NUM
dpc-5967	13	8	-	-	SYM
dpc-5967	13	9	7627	7627	NUM
dpc-5967	13	10	.	.	PUNCT
dpc-5967	14	1	email	email	NOUN
dpc-5967	14	2	:	:	PUNCT
dpc-5967	14	3	titou.medic@gmail.com	titou.medic@gmail.com	X
dpc-5967	14	4	to	to	ADP
dpc-5967	14	5	the	the	DET
dpc-5967	14	6	editor	editor	NOUN
dpc-5967	14	7	,	,	PUNCT
dpc-5967	14	8	recent	recent	ADJ
dpc-5967	14	9	advancements	advancement	NOUN
dpc-5967	14	10	in	in	ADP
dpc-5967	14	11	the	the	DET
dpc-5967	14	12	understanding	understanding	NOUN
dpc-5967	14	13	of	of	ADP
dpc-5967	14	14	prurigo	prurigo	PROPN
dpc-5967	14	15	nodularis	nodularis	PROPN
dpc-5967	14	16	(	(	PUNCT
dpc-5967	14	17	pn	pn	NOUN
dpc-5967	14	18	)	)	PUNCT
dpc-5967	14	19	immunopathogenesis	immunopathogenesis	NOUN
dpc-5967	14	20	have	have	AUX
dpc-5967	14	21	led	lead	VERB
dpc-5967	14	22	to	to	ADP
dpc-5967	14	23	more	more	ADJ
dpc-5967	14	24	treatment	treatment	NOUN
dpc-5967	14	25	choices	choice	NOUN
dpc-5967	14	26	.	.	PUNCT
dpc-5967	15	1	since	since	SCONJ
dpc-5967	15	2	august	august	PROPN
dpc-5967	15	3	2024	2024	NUM
dpc-5967	15	4	,	,	PUNCT
dpc-5967	15	5	nemolizumab	nemolizumab	NOUN
dpc-5967	15	6	has	have	AUX
dpc-5967	15	7	been	be	AUX
dpc-5967	15	8	approved	approve	VERB
dpc-5967	15	9	by	by	ADP
dpc-5967	15	10	the	the	DET
dpc-5967	15	11	us	us	PROPN
dpc-5967	15	12	food	food	NOUN
dpc-5967	15	13	and	and	CCONJ
dpc-5967	15	14	drug	drug	PROPN
dpc-5967	15	15	administration	administration	NOUN
dpc-5967	15	16	[	[	X
dpc-5967	15	17	1	1	NUM
dpc-5967	15	18	]	]	PUNCT
dpc-5967	15	19	.	.	PUNCT
dpc-5967	16	1	we	we	PRON
dpc-5967	16	2	systematically	systematically	ADV
dpc-5967	16	3	reviewed	review	VERB
dpc-5967	16	4	the	the	DET
dpc-5967	16	5	efficacy	efficacy	NOUN
dpc-5967	16	6	and	and	CCONJ
dpc-5967	16	7	safety	safety	NOUN
dpc-5967	16	8	of	of	ADP
dpc-5967	16	9	nemolizumab	nemolizumab	NOUN
dpc-5967	16	10	among	among	ADP
dpc-5967	16	11	existing	exist	VERB
dpc-5967	16	12	randomized	randomize	VERB
dpc-5967	16	13	,	,	PUNCT
dpc-5967	16	14	double	double	ADJ
dpc-5967	16	15	-	-	PUNCT
dpc-5967	16	16	blinded	blind	VERB
dpc-5967	16	17	,	,	PUNCT
dpc-5967	16	18	and	and	CCONJ
dpc-5967	16	19	placebo	placebo	NOUN
dpc-5967	16	20	-	-	PUNCT
dpc-5967	16	21	controlled	control	VERB
dpc-5967	16	22	clinical	clinical	ADJ
dpc-5967	16	23	trials	trial	NOUN
dpc-5967	16	24	.	.	PUNCT
dpc-5967	17	1	we	we	PRON
dpc-5967	17	2	performed	perform	VERB
dpc-5967	17	3	every	every	DET
dpc-5967	17	4	step	step	NOUN
dpc-5967	17	5	according	accord	VERB
dpc-5967	17	6	to	to	ADP
dpc-5967	17	7	the	the	DET
dpc-5967	17	8	preferred	preferred	ADJ
dpc-5967	17	9	reporting	reporting	NOUN
dpc-5967	17	10	items	item	NOUN
dpc-5967	17	11	for	for	ADP
dpc-5967	17	12	systematic	systematic	ADJ
dpc-5967	17	13	reviews	review	NOUN
dpc-5967	17	14	and	and	CCONJ
dpc-5967	17	15	meta	meta	ADJ
dpc-5967	17	16	-	-	PUNCT
dpc-5967	17	17	analyses	analysis	NOUN
dpc-5967	17	18	guidelines	guideline	NOUN
dpc-5967	17	19	.	.	PUNCT
dpc-5967	18	1	we	we	PRON
dpc-5967	18	2	searched	search	VERB
dpc-5967	18	3	electronic	electronic	ADJ
dpc-5967	18	4	databases	database	NOUN
dpc-5967	18	5	(	(	PUNCT
dpc-5967	18	6	embase	embase	NOUN
dpc-5967	18	7	,	,	PUNCT
dpc-5967	18	8	scopus	scopus	PROPN
dpc-5967	18	9	,	,	PUNCT
dpc-5967	18	10	pubmed	pubmed	PROPN
dpc-5967	18	11	,	,	PUNCT
dpc-5967	18	12	and	and	CCONJ
dpc-5967	18	13	cochrane	cochrane	NOUN
dpc-5967	18	14	)	)	PUNCT
dpc-5967	18	15	from	from	ADP
dpc-5967	18	16	their	their	PRON
dpc-5967	18	17	inception	inception	NOUN
dpc-5967	18	18	to	to	ADP
dpc-5967	18	19	01	01	NUM
dpc-5967	18	20	january	january	PROPN
dpc-5967	18	21	2025	2025	NUM
dpc-5967	18	22	.	.	PUNCT
dpc-5967	19	1	the	the	DET
dpc-5967	19	2	search	search	NOUN
dpc-5967	19	3	strategies	strategy	NOUN
dpc-5967	19	4	and	and	CCONJ
dpc-5967	19	5	methods	method	NOUN
dpc-5967	19	6	are	be	AUX
dpc-5967	19	7	provided	provide	VERB
dpc-5967	19	8	in	in	ADP
dpc-5967	19	9	supplementary	supplementary	ADJ
dpc-5967	19	10	figure	figure	NOUN
dpc-5967	19	11	a1	a1	NOUN
dpc-5967	19	12	and	and	CCONJ
dpc-5967	19	13	materials	material	NOUN
dpc-5967	19	14	(	(	PUNCT
dpc-5967	19	15	available	available	ADJ
dpc-5967	19	16	via	via	ADP
dpc-5967	19	17	mendeley	mendeley	NOUN
dpc-5967	19	18	at	at	ADP
dpc-5967	19	19	https://data.mendeley.com/datasets/tghtskv98w/1	https://data.mendeley.com/datasets/tghtskv98w/1	NOUN
dpc-5967	19	20	)	)	PUNCT
dpc-5967	19	21	.	.	PUNCT
dpc-5967	20	1	finally	finally	ADV
dpc-5967	20	2	,	,	PUNCT
dpc-5967	20	3	this	this	DET
dpc-5967	20	4	study	study	NOUN
dpc-5967	20	5	included	include	VERB
dpc-5967	20	6	four	four	NUM
dpc-5967	20	7	studies	study	NOUN
dpc-5967	20	8	involving	involve	VERB
dpc-5967	20	9	560	560	NUM
dpc-5967	20	10	patients	patient	NOUN
dpc-5967	20	11	in	in	ADP
dpc-5967	20	12	experimental	experimental	ADJ
dpc-5967	20	13	groups	group	NOUN
dpc-5967	20	14	and	and	CCONJ
dpc-5967	20	15	299	299	NUM
dpc-5967	20	16	patients	patient	NOUN
dpc-5967	20	17	in	in	ADP
dpc-5967	20	18	control	control	NOUN
dpc-5967	20	19	groups	group	NOUN
dpc-5967	20	20	.	.	PUNCT
dpc-5967	21	1	we	we	PRON
dpc-5967	21	2	summarized	summarize	VERB
dpc-5967	21	3	the	the	DET
dpc-5967	21	4	primary	primary	ADJ
dpc-5967	21	5	and	and	CCONJ
dpc-5967	21	6	second	second	ADJ
dpc-5967	21	7	endpoints	endpoint	NOUN
dpc-5967	21	8	of	of	ADP
dpc-5967	21	9	each	each	DET
dpc-5967	21	10	study	study	NOUN
dpc-5967	21	11	in	in	ADP
dpc-5967	21	12	supplementary	supplementary	ADJ
dpc-5967	21	13	table	table	NOUN
dpc-5967	21	14	1	1	NUM
dpc-5967	21	15	(	(	PUNCT
dpc-5967	21	16	available	available	ADJ
dpc-5967	21	17	via	via	ADP
dpc-5967	21	18	mendeley	mendeley	NOUN
dpc-5967	21	19	at	at	ADP
dpc-5967	21	20	https://data.mendeley.com/datasets/tghtskv98w/1	https://data.mendeley.com/datasets/tghtskv98w/1	NOUN
dpc-5967	21	21	)	)	PUNCT
dpc-5967	21	22	.	.	PUNCT
dpc-5967	22	1	overall	overall	ADV
dpc-5967	22	2	,	,	PUNCT
dpc-5967	22	3	compared	compare	VERB
dpc-5967	22	4	with	with	ADP
dpc-5967	22	5	placebos	placebo	NOUN
dpc-5967	22	6	,	,	PUNCT
dpc-5967	22	7	the	the	DET
dpc-5967	22	8	use	use	NOUN
dpc-5967	22	9	of	of	ADP
dpc-5967	22	10	nemolizumab	nemolizumab	NOUN
dpc-5967	22	11	treatment	treatment	NOUN
dpc-5967	22	12	showed	show	VERB
dpc-5967	22	13	a	a	DET
dpc-5967	22	14	significant	significant	ADJ
dpc-5967	22	15	improvement	improvement	NOUN
dpc-5967	22	16	in	in	ADP
dpc-5967	22	17	the	the	DET
dpc-5967	22	18	lesion	lesion	NOUN
dpc-5967	22	19	score	score	NOUN
dpc-5967	22	20	and	and	CCONJ
dpc-5967	22	21	pruritus	pruritus	NOUN
dpc-5967	22	22	from	from	ADP
dpc-5967	22	23	week	week	NOUN
dpc-5967	22	24	4	4	NUM
dpc-5967	22	25	:	:	PUNCT
dpc-5967	22	26	peak	peak	NOUN
dpc-5967	22	27	pruritus	pruritus	PROPN
dpc-5967	22	28	numerical	numerical	ADJ
dpc-5967	22	29	rating	rating	NOUN
dpc-5967	22	30	scale	scale	NOUN
dpc-5967	22	31	(	(	PUNCT
dpc-5967	22	32	pp	pp	NOUN
dpc-5967	22	33	-	-	PUNCT
dpc-5967	22	34	nrs	nrs	NOUN
dpc-5967	22	35	)	)	PUNCT
dpc-5967	22	36	improvement	improvement	NOUN
dpc-5967	22	37	≥4	≥4	PROPN
dpc-5967	22	38	points	point	NOUN
dpc-5967	22	39	(	(	PUNCT
dpc-5967	22	40	odds	odd	NOUN
dpc-5967	22	41	ratio	ratio	NOUN
dpc-5967	22	42	(	(	PUNCT
dpc-5967	22	43	or	or	CCONJ
dpc-5967	22	44	):	):	PUNCT
dpc-5967	22	45	9.27	9.27	NUM
dpc-5967	22	46	;	;	PUNCT
dpc-5967	22	47	95	95	NUM
dpc-5967	22	48	%	%	NOUN
dpc-5967	22	49	confidence	confidence	NOUN
dpc-5967	22	50	interval	interval	NOUN
dpc-5967	22	51	(	(	PUNCT
dpc-5967	22	52	ci	ci	NOUN
dpc-5967	22	53	):	):	PUNCT
dpc-5967	22	54	5.08	5.08	NUM
dpc-5967	22	55	–	–	PUNCT
dpc-5967	22	56	16.90	16.90	NUM
dpc-5967	22	57	;	;	PUNCT
dpc-5967	22	58	p<0.00001	p<0.00001	NUM
dpc-5967	22	59	)	)	PUNCT
dpc-5967	22	60	and	and	CCONJ
dpc-5967	22	61	investigators	investigator	NOUN
dpc-5967	22	62	’	’	PART
dpc-5967	22	63	global	global	ADJ
dpc-5967	22	64	assessment	assessment	NOUN
dpc-5967	22	65	score	score	NOUN
dpc-5967	22	66	(	(	PUNCT
dpc-5967	22	67	iga	iga	PROPN
dpc-5967	22	68	0/1	0/1	NUM
dpc-5967	22	69	)	)	PUNCT
dpc-5967	22	70	(	(	PUNCT
dpc-5967	22	71	or	or	CCONJ
dpc-5967	22	72	:	:	PUNCT
dpc-5967	22	73	3.24	3.24	NUM
dpc-5967	22	74	;	;	PUNCT
dpc-5967	22	75	95	95	NUM
dpc-5967	22	76	%	%	NOUN
dpc-5967	22	77	ci	ci	NOUN
dpc-5967	22	78	:	:	PUNCT
dpc-5967	22	79	0.45–23.49	0.45–23.49	NUM
dpc-5967	22	80	;	;	PUNCT
dpc-5967	22	81	p=0.02	p=0.02	NOUN
dpc-5967	22	82	)	)	PUNCT
dpc-5967	22	83	(	(	PUNCT
dpc-5967	22	84	figures	figure	NOUN
dpc-5967	22	85	1	1	NUM
dpc-5967	22	86	and	and	CCONJ
dpc-5967	22	87	2	2	NUM
dpc-5967	22	88	)	)	PUNCT
dpc-5967	22	89	.	.	PUNCT
dpc-5967	23	1	the	the	DET
dpc-5967	23	2	intense	intense	ADJ
dpc-5967	23	3	itching	itching	NOUN
dpc-5967	23	4	associated	associate	VERB
dpc-5967	23	5	with	with	ADP
dpc-5967	23	6	pn	pn	PROPN
dpc-5967	23	7	significantly	significantly	ADV
dpc-5967	23	8	affects	affect	VERB
dpc-5967	23	9	patients	patient	NOUN
dpc-5967	23	10	’	'	PUNCT
dpc-5967	23	11	quality	quality	NOUN
dpc-5967	23	12	of	of	ADP
dpc-5967	23	13	life	life	NOUN
dpc-5967	23	14	,	,	PUNCT
dpc-5967	23	15	leading	lead	VERB
dpc-5967	23	16	to	to	ADP
dpc-5967	23	17	sleep	sleep	NOUN
dpc-5967	23	18	disturbances	disturbance	NOUN
dpc-5967	23	19	,	,	PUNCT
dpc-5967	23	20	particularly	particularly	ADV
dpc-5967	23	21	during	during	ADP
dpc-5967	23	22	the	the	DET
dpc-5967	23	23	evening	evening	NOUN
dpc-5967	23	24	[	[	X
dpc-5967	23	25	2	2	NUM
dpc-5967	23	26	]	]	PUNCT
dpc-5967	23	27	.	.	PUNCT
dpc-5967	24	1	the	the	DET
dpc-5967	24	2	results	result	NOUN
dpc-5967	24	3	of	of	ADP
dpc-5967	24	4	the	the	DET
dpc-5967	24	5	meta	meta	ADJ
dpc-5967	24	6	-	-	PUNCT
dpc-5967	24	7	analysis	analysis	NOUN
dpc-5967	24	8	indicated	indicate	VERB
dpc-5967	24	9	that	that	SCONJ
dpc-5967	24	10	nemolizumab	nemolizumab	NOUN
dpc-5967	24	11	has	have	VERB
dpc-5967	24	12	better	well	ADJ
dpc-5967	24	13	performance	performance	NOUN
dpc-5967	24	14	than	than	SCONJ
dpc-5967	24	15	does	do	VERB
dpc-5967	24	16	the	the	DET
dpc-5967	24	17	placebo	placebo	NOUN
dpc-5967	24	18	on	on	ADP
dpc-5967	24	19	the	the	DET
dpc-5967	24	20	sleep	sleep	NOUN
dpc-5967	24	21	disturbance	disturbance	NOUN
dpc-5967	24	22	numerical	numerical	ADJ
dpc-5967	24	23	rating	rating	NOUN
dpc-5967	24	24	scale	scale	NOUN
dpc-5967	24	25	(	(	PUNCT
dpc-5967	24	26	sd	sd	NOUN
dpc-5967	24	27	-	-	PUNCT
dpc-5967	24	28	nrs	nrs	NOUN
dpc-5967	24	29	)	)	PUNCT
dpc-5967	24	30	(	(	PUNCT
dpc-5967	24	31	or	or	CCONJ
dpc-5967	24	32	:	:	PUNCT
dpc-5967	24	33	6.33	6.33	NUM
dpc-5967	24	34	;	;	PUNCT
dpc-5967	24	35	95	95	NUM
dpc-5967	24	36	%	%	NOUN
dpc-5967	24	37	ci	ci	NOUN
dpc-5967	24	38	:	:	PUNCT
dpc-5967	24	39	3.51–11.41	3.51–11.41	NUM
dpc-5967	24	40	;	;	PUNCT
dpc-5967	24	41	p<0.00001	p<0.00001	NUM
dpc-5967	24	42	)	)	PUNCT
dpc-5967	24	43	.	.	PUNCT
dpc-5967	25	1	(	(	PUNCT
dpc-5967	25	2	supplementary	supplementary	ADJ
dpc-5967	25	3	figure	figure	NOUN
dpc-5967	25	4	a2	a2	PROPN
dpc-5967	25	5	,	,	PUNCT
dpc-5967	25	6	available	available	ADJ
dpc-5967	25	7	via	via	ADP
dpc-5967	25	8	mendeley	mendeley	NOUN
dpc-5967	25	9	at	at	ADP
dpc-5967	25	10	https://data.mendeley.com/datasets/	https://data.mendeley.com/datasets/	NOUN
dpc-5967	25	11	tghtskv98w/1	tghtskv98w/1	NOUN
dpc-5967	25	12	)	)	PUNCT
dpc-5967	25	13	.	.	PUNCT
dpc-5967	26	1	2	2	NUM
dpc-5967	26	2	letter	letter	NOUN
dpc-5967	26	3	to	to	ADP
dpc-5967	26	4	the	the	DET
dpc-5967	26	5	editor	editor	NOUN
dpc-5967	26	6	|	|	ADV
dpc-5967	26	7	dermatol	dermatol	ADJ
dpc-5967	26	8	pract	pract	NOUN
dpc-5967	26	9	concept	concept	NOUN
dpc-5967	26	10	.	.	PUNCT
dpc-5967	27	1	2025;15(4):5967	2025;15(4):5967	NUM
dpc-5967	27	2	the	the	DET
dpc-5967	27	3	safety	safety	NOUN
dpc-5967	27	4	profile	profile	NOUN
dpc-5967	27	5	and	and	CCONJ
dpc-5967	27	6	efficacy	efficacy	NOUN
dpc-5967	27	7	of	of	ADP
dpc-5967	27	8	nemolizumab	nemolizumab	NOUN
dpc-5967	27	9	were	be	AUX
dpc-5967	27	10	similar	similar	ADJ
dpc-5967	27	11	to	to	ADP
dpc-5967	27	12	dupilumab	dupilumab	NOUN
dpc-5967	27	13	[	[	X
dpc-5967	27	14	3	3	NUM
dpc-5967	27	15	]	]	PUNCT
dpc-5967	27	16	.	.	PUNCT
dpc-5967	28	1	nemolizumab	nemolizumab	PROPN
dpc-5967	28	2	demonstrated	demonstrate	VERB
dpc-5967	28	3	the	the	DET
dpc-5967	28	4	highest	high	ADJ
dpc-5967	28	5	risk	risk	NOUN
dpc-5967	28	6	of	of	ADP
dpc-5967	28	7	aes	aes	PROPN
dpc-5967	28	8	,	,	PUNCT
dpc-5967	28	9	and	and	CCONJ
dpc-5967	28	10	the	the	DET
dpc-5967	28	11	incidence	incidence	NOUN
dpc-5967	28	12	was	be	AUX
dpc-5967	28	13	significantly	significantly	ADV
dpc-5967	28	14	higher	high	ADJ
dpc-5967	28	15	than	than	ADP
dpc-5967	28	16	that	that	PRON
dpc-5967	28	17	of	of	ADP
dpc-5967	28	18	the	the	DET
dpc-5967	28	19	placebo	placebo	NOUN
dpc-5967	28	20	.	.	PUNCT
dpc-5967	29	1	twenty	twenty	NUM
dpc-5967	29	2	-	-	PUNCT
dpc-5967	29	3	nine	nine	NUM
dpc-5967	29	4	patients	patient	NOUN
dpc-5967	29	5	in	in	ADP
dpc-5967	29	6	the	the	DET
dpc-5967	29	7	nemolizumab	nemolizumab	NOUN
dpc-5967	29	8	-	-	PUNCT
dpc-5967	29	9	treated	treat	VERB
dpc-5967	29	10	group	group	NOUN
dpc-5967	29	11	experienced	experience	VERB
dpc-5967	29	12	serious	serious	ADJ
dpc-5967	29	13	aes	aes	PROPN
dpc-5967	29	14	,	,	PUNCT
dpc-5967	29	15	and	and	CCONJ
dpc-5967	29	16	22	22	NUM
dpc-5967	29	17	of	of	ADP
dpc-5967	29	18	them	they	PRON
dpc-5967	29	19	discontinued	discontinue	VERB
dpc-5967	29	20	the	the	DET
dpc-5967	29	21	treatment	treatment	NOUN
dpc-5967	29	22	.	.	PUNCT
dpc-5967	30	1	the	the	DET
dpc-5967	30	2	most	most	ADV
dpc-5967	30	3	commonly	commonly	ADV
dpc-5967	30	4	reported	report	VERB
dpc-5967	30	5	serious	serious	ADJ
dpc-5967	30	6	aes	aes	PROPN
dpc-5967	30	7	of	of	ADP
dpc-5967	30	8	nemolizumab	nemolizumab	NOUN
dpc-5967	30	9	were	be	AUX
dpc-5967	30	10	infection	infection	NOUN
dpc-5967	30	11	(	(	PUNCT
dpc-5967	30	12	or	or	CCONJ
dpc-5967	30	13	:	:	PUNCT
dpc-5967	30	14	0.81	0.81	NUM
dpc-5967	30	15	;	;	PUNCT
dpc-5967	30	16	95	95	NUM
dpc-5967	30	17	%	%	NOUN
dpc-5967	30	18	ci	ci	NOUN
dpc-5967	30	19	:	:	PUNCT
dpc-5967	30	20	0.53–1.24	0.53–1.24	NUM
dpc-5967	30	21	;	;	PUNCT
dpc-5967	30	22	p=0.52	p=0.52	NOUN
dpc-5967	30	23	)	)	PUNCT
dpc-5967	30	24	,	,	PUNCT
dpc-5967	30	25	atopic	atopic	NOUN
dpc-5967	30	26	dermatitis	dermatitis	NOUN
dpc-5967	30	27	(	(	PUNCT
dpc-5967	30	28	or	or	CCONJ
dpc-5967	30	29	:	:	PUNCT
dpc-5967	30	30	2.68	2.68	NUM
dpc-5967	30	31	;	;	PUNCT
dpc-5967	30	32	95	95	NUM
dpc-5967	30	33	%	%	NOUN
dpc-5967	30	34	ci	ci	NOUN
dpc-5967	30	35	:	:	PUNCT
dpc-5967	30	36	0.54–13.24	0.54–13.24	NUM
dpc-5967	30	37	;	;	PUNCT
dpc-5967	30	38	p=0.21	p=0.21	NOUN
dpc-5967	30	39	)	)	PUNCT
dpc-5967	30	40	,	,	PUNCT
dpc-5967	30	41	peripheral	peripheral	ADJ
dpc-5967	30	42	or	or	CCONJ
dpc-5967	30	43	facial	facial	ADJ
dpc-5967	30	44	edema	edema	NOUN
dpc-5967	30	45	(	(	PUNCT
dpc-5967	30	46	or	or	CCONJ
dpc-5967	30	47	:	:	PUNCT
dpc-5967	30	48	1.83	1.83	NUM
dpc-5967	30	49	;	;	PUNCT
dpc-5967	30	50	95	95	NUM
dpc-5967	30	51	%	%	NOUN
dpc-5967	30	52	ci	ci	NOUN
dpc-5967	30	53	:	:	PUNCT
dpc-5967	30	54	0.50–6.69	0.50–6.69	NUM
dpc-5967	30	55	;	;	PUNCT
dpc-5967	30	56	p=0.70	p=0.70	NOUN
dpc-5967	30	57	)	)	PUNCT
dpc-5967	30	58	,	,	PUNCT
dpc-5967	30	59	and	and	CCONJ
dpc-5967	30	60	asthma	asthma	NOUN
dpc-5967	30	61	(	(	PUNCT
dpc-5967	30	62	or	or	CCONJ
dpc-5967	30	63	:	:	PUNCT
dpc-5967	30	64	1.35	1.35	NUM
dpc-5967	30	65	;	;	PUNCT
dpc-5967	30	66	95	95	NUM
dpc-5967	30	67	%	%	NOUN
dpc-5967	30	68	ci	ci	NOUN
dpc-5967	30	69	:	:	PUNCT
dpc-5967	30	70	0.35–5.16	0.35–5.16	NUM
dpc-5967	30	71	;	;	PUNCT
dpc-5967	30	72	p=0.77	p=0.77	ADJ
dpc-5967	30	73	)	)	PUNCT
dpc-5967	30	74	,	,	PUNCT
dpc-5967	30	75	all	all	PRON
dpc-5967	30	76	of	of	ADP
dpc-5967	30	77	which	which	PRON
dpc-5967	30	78	were	be	AUX
dpc-5967	30	79	mild	mild	ADJ
dpc-5967	30	80	-	-	PUNCT
dpc-5967	30	81	to	to	ADP
dpc-5967	30	82	-	-	PUNCT
dpc-5967	30	83	moderate	moderate	ADJ
dpc-5967	30	84	in	in	ADP
dpc-5967	30	85	severity	severity	NOUN
dpc-5967	30	86	(	(	PUNCT
dpc-5967	30	87	supplementary	supplementary	ADJ
dpc-5967	30	88	figure	figure	NOUN
dpc-5967	30	89	a3	a3	NOUN
dpc-5967	30	90	,	,	PUNCT
dpc-5967	30	91	available	available	ADJ
dpc-5967	30	92	via	via	ADP
dpc-5967	30	93	mendeley	mendeley	NOUN
dpc-5967	30	94	at	at	ADP
dpc-5967	30	95	https://data.mendeley.com/	https://data.mendeley.com/	PROPN
dpc-5967	30	96	datasets	dataset	NOUN
dpc-5967	30	97	/	/	SYM
dpc-5967	30	98	tghtskv98w/1	tghtskv98w/1	NOUN
dpc-5967	30	99	)	)	PUNCT
dpc-5967	30	100	.	.	PUNCT
dpc-5967	31	1	in	in	ADP
dpc-5967	31	2	conclusion	conclusion	NOUN
dpc-5967	31	3	,	,	PUNCT
dpc-5967	31	4	this	this	DET
dpc-5967	31	5	meta	meta	ADJ
dpc-5967	31	6	-	-	PUNCT
dpc-5967	31	7	analysis	analysis	NOUN
dpc-5967	31	8	showed	show	VERB
dpc-5967	31	9	that	that	SCONJ
dpc-5967	31	10	nemolizumab	nemolizumab	NOUN
dpc-5967	31	11	is	be	AUX
dpc-5967	31	12	a	a	DET
dpc-5967	31	13	promising	promising	ADJ
dpc-5967	31	14	treatment	treatment	NOUN
dpc-5967	31	15	option	option	NOUN
dpc-5967	31	16	for	for	ADP
dpc-5967	31	17	pn	pn	PROPN
dpc-5967	31	18	.	.	PROPN
dpc-5967	31	19	further	further	PROPN
dpc-5967	31	20	studies	study	NOUN
dpc-5967	31	21	with	with	ADP
dpc-5967	31	22	long	long	ADJ
dpc-5967	31	23	follow	follow	NOUN
dpc-5967	31	24	-	-	PUNCT
dpc-5967	31	25	up	up	NOUN
dpc-5967	31	26	will	will	AUX
dpc-5967	31	27	be	be	AUX
dpc-5967	31	28	needed	need	VERB
dpc-5967	31	29	to	to	PART
dpc-5967	31	30	fully	fully	ADV
dpc-5967	31	31	elucidate	elucidate	VERB
dpc-5967	31	32	the	the	DET
dpc-5967	31	33	safety	safety	NOUN
dpc-5967	31	34	profile	profile	NOUN
dpc-5967	31	35	of	of	ADP
dpc-5967	31	36	nemolizumab	nemolizumab	NOUN
dpc-5967	31	37	.	.	PUNCT
dpc-5967	32	1	figure	figure	NOUN
dpc-5967	32	2	1	1	NUM
dpc-5967	32	3	.	.	PUNCT
dpc-5967	32	4	forest	forest	NOUN
dpc-5967	32	5	plot	plot	NOUN
dpc-5967	32	6	of	of	ADP
dpc-5967	32	7	effect	effect	NOUN
dpc-5967	32	8	of	of	ADP
dpc-5967	32	9	nemolizumab	nemolizumab	NOUN
dpc-5967	32	10	treatment	treatment	NOUN
dpc-5967	32	11	on	on	ADP
dpc-5967	32	12	pp	pp	ADJ
dpc-5967	32	13	-	-	PUNCT
dpc-5967	32	14	nrs	nrs	NOUN
dpc-5967	32	15	improvement	improvement	NOUN
dpc-5967	32	16	≥4	≥4	PROPN
dpc-5967	32	17	points	point	VERB
dpc-5967	32	18	in	in	ADP
dpc-5967	32	19	prurigo	prurigo	PROPN
dpc-5967	32	20	nodularis	nodularis	PROPN
dpc-5967	32	21	patients	patient	NOUN
dpc-5967	32	22	.	.	PUNCT
dpc-5967	33	1	figure	figure	NOUN
dpc-5967	33	2	2	2	NUM
dpc-5967	33	3	.	.	PUNCT
dpc-5967	33	4	forest	forest	NOUN
dpc-5967	33	5	plot	plot	NOUN
dpc-5967	33	6	of	of	ADP
dpc-5967	33	7	effect	effect	NOUN
dpc-5967	33	8	of	of	ADP
dpc-5967	33	9	nemolizumab	nemolizumab	NOUN
dpc-5967	33	10	treatment	treatment	NOUN
dpc-5967	33	11	on	on	ADP
dpc-5967	33	12	investigator	investigator	NOUN
dpc-5967	33	13	’s	’s	PART
dpc-5967	33	14	global	global	ADJ
dpc-5967	33	15	assessment	assessment	NOUN
dpc-5967	33	16	score	score	NOUN
dpc-5967	33	17	(	(	PUNCT
dpc-5967	33	18	iga	iga	PROPN
dpc-5967	33	19	0/1	0/1	NUM
dpc-5967	33	20	)	)	PUNCT
dpc-5967	33	21	in	in	ADP
dpc-5967	33	22	prurigo	prurigo	PROPN
dpc-5967	33	23	nodularis	nodularis	PROPN
dpc-5967	33	24	patients	patient	NOUN
dpc-5967	33	25	.	.	PUNCT
dpc-5967	34	1	letter	letter	NOUN
dpc-5967	34	2	to	to	ADP
dpc-5967	34	3	the	the	DET
dpc-5967	34	4	editor	editor	NOUN
dpc-5967	34	5	|	|	ADV
dpc-5967	34	6	dermatol	dermatol	ADJ
dpc-5967	34	7	pract	pract	NOUN
dpc-5967	34	8	concept	concept	NOUN
dpc-5967	34	9	.	.	PUNCT
dpc-5967	35	1	2025;15(4):5967	2025;15(4):5967	NUM
dpc-5967	35	2	3	3	NUM
dpc-5967	35	3	references	reference	NOUN
dpc-5967	35	4	1	1	NUM
dpc-5967	35	5	.	.	PUNCT
dpc-5967	35	6	galderma	galderma	NOUN
dpc-5967	35	7	receives	receive	VERB
dpc-5967	35	8	u.s	u.s	PROPN
dpc-5967	35	9	.	.	PROPN
dpc-5967	35	10	fda	fda	PROPN
dpc-5967	35	11	approval	approval	PROPN
dpc-5967	35	12	for	for	ADP
dpc-5967	35	13	nemluvio	nemluvio	NOUN
dpc-5967	35	14	(	(	PUNCT
dpc-5967	35	15	nemolizumab	nemolizumab	NOUN
dpc-5967	35	16	)	)	PUNCT
dpc-5967	35	17	for	for	ADP
dpc-5967	35	18	adult	adult	NOUN
dpc-5967	35	19	patients	patient	NOUN
dpc-5967	35	20	living	live	VERB
dpc-5967	35	21	with	with	ADP
dpc-5967	35	22	prurigo	prurigo	PROPN
dpc-5967	35	23	nodularis	nodularis	PROPN
dpc-5967	35	24	.	.	PUNCT
dpc-5967	36	1	news	news	NOUN
dpc-5967	36	2	release	release	NOUN
dpc-5967	36	3	.	.	PUNCT
dpc-5967	37	1	galderma	galderma	PROPN
dpc-5967	37	2	.	.	PUNCT
dpc-5967	38	1	august	august	PROPN
dpc-5967	38	2	13	13	NUM
dpc-5967	38	3	,	,	PUNCT
dpc-5967	38	4	2024	2024	NUM
dpc-5967	38	5	.	.	PUNCT
dpc-5967	39	1	accessed	access	VERB
dpc-5967	39	2	january	january	PROPN
dpc-5967	39	3	1	1	NUM
dpc-5967	39	4	,	,	PUNCT
dpc-5967	39	5	2025	2025	NUM
dpc-5967	39	6	.	.	PUNCT
dpc-5967	40	1	2	2	X
dpc-5967	40	2	.	.	X
dpc-5967	40	3	ständer	ständer	NOUN
dpc-5967	40	4	s	s	PROPN
dpc-5967	40	5	,	,	PUNCT
dpc-5967	40	6	fofana	fofana	PROPN
dpc-5967	40	7	f	f	PROPN
dpc-5967	40	8	,	,	PUNCT
dpc-5967	40	9	dias	dias	PROPN
dpc-5967	40	10	-	-	PUNCT
dpc-5967	40	11	barbosa	barbosa	PROPN
dpc-5967	40	12	c	c	PROPN
dpc-5967	40	13	,	,	PUNCT
dpc-5967	40	14	et	et	PROPN
dpc-5967	40	15	al	al	PROPN
dpc-5967	40	16	.	.	PUNCT
dpc-5967	41	1	the	the	DET
dpc-5967	41	2	sleep	sleep	NOUN
dpc-5967	41	3	disturbance	disturbance	NOUN
dpc-5967	41	4	numerical	numerical	ADJ
dpc-5967	41	5	rating	rating	NOUN
dpc-5967	41	6	scale	scale	NOUN
dpc-5967	41	7	:	:	PUNCT
dpc-5967	41	8	content	content	NOUN
dpc-5967	41	9	validity	validity	NOUN
dpc-5967	41	10	,	,	PUNCT
dpc-5967	41	11	psychometric	psychometric	ADJ
dpc-5967	41	12	validation	validation	NOUN
dpc-5967	41	13	,	,	PUNCT
dpc-5967	41	14	and	and	CCONJ
dpc-5967	41	15	meaningful	meaningful	ADJ
dpc-5967	41	16	within	within	ADP
dpc-5967	41	17	-	-	PUNCT
dpc-5967	41	18	patient	patient	NOUN
dpc-5967	41	19	change	change	NOUN
dpc-5967	41	20	in	in	ADP
dpc-5967	41	21	prurigo	prurigo	PROPN
dpc-5967	41	22	nodularis	nodularis	PROPN
dpc-5967	41	23	.	.	PUNCT
dpc-5967	42	1	dermatol	dermatol	NOUN
dpc-5967	42	2	ther	ther	ADV
dpc-5967	42	3	(	(	PUNCT
dpc-5967	42	4	heidelb	heidelb	NOUN
dpc-5967	42	5	)	)	PUNCT
dpc-5967	42	6	.	.	PUNCT
dpc-5967	43	1	2023;13(7):1587	2023;13(7):1587	NUM
dpc-5967	43	2	-	-	SYM
dpc-5967	43	3	1602	1602	NUM
dpc-5967	43	4	.	.	PUNCT
dpc-5967	44	1	doi:10.1007	doi:10.1007	PROPN
dpc-5967	44	2	/	/	SYM
dpc-5967	44	3	s13555	s13555	PROPN
dpc-5967	44	4	-	-	PUNCT
dpc-5967	44	5	023	023	NUM
dpc-5967	44	6	-	-	PUNCT
dpc-5967	44	7	00962	00962	NUM
dpc-5967	44	8	-	-	PUNCT
dpc-5967	44	9	8	8	NUM
dpc-5967	44	10	.	.	PUNCT
dpc-5967	45	1	pmid	pmid	NOUN
dpc-5967	45	2	:	:	PUNCT
dpc-5967	45	3	37329468	37329468	NUM
dpc-5967	45	4	.	.	PUNCT
dpc-5967	46	1	3	3	X
dpc-5967	46	2	.	.	X
dpc-5967	46	3	brooks	brooks	PROPN
dpc-5967	46	4	sg	sg	PROPN
dpc-5967	46	5	,	,	PUNCT
dpc-5967	46	6	yosipovitch	yosipovitch	PROPN
dpc-5967	46	7	g.	g.	PROPN
dpc-5967	46	8	a	a	DET
dpc-5967	46	9	critical	critical	ADJ
dpc-5967	46	10	evaluation	evaluation	NOUN
dpc-5967	46	11	of	of	ADP
dpc-5967	46	12	nemolizumab	nemolizumab	NOUN
dpc-5967	46	13	for	for	ADP
dpc-5967	46	14	prurigo	prurigo	PROPN
dpc-5967	46	15	nodularis	nodularis	PROPN
dpc-5967	46	16	.	.	PUNCT
dpc-5967	47	1	expert	expert	NOUN
dpc-5967	47	2	rev	rev	VERB
dpc-5967	47	3	clin	clin	PROPN
dpc-5967	47	4	immunol	immunol	NOUN
dpc-5967	47	5	.	.	PUNCT
dpc-5967	48	1	2024;20(6):577	2024;20(6):577	NUM
dpc-5967	48	2	-	-	SYM
dpc-5967	48	3	587	587	NUM
dpc-5967	48	4	.	.	PUNCT
dpc-5967	49	1	doi:10.1080/1744666x.2024.2306225	doi:10.1080/1744666x.2024.2306225	X
dpc-5967	49	2	.	.	PUNCT
dpc-5967	50	1	pmid	pmid	NOUN
dpc-5967	50	2	:	:	PUNCT
dpc-5967	50	3	38217530	38217530	NUM
dpc-5967	50	4	.	.	PUNCT